Non-infectious Uveitis
Conditions
Keywords
non-infectious uveitis
Brief summary
prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.
Detailed description
Description of the clinical characteristics and evolution in a large cohort of patients with non-infectious uveitis, allowing to identify prognostic or predictive factors of response after treatment of these different forms of non-infectious uveitis of the posterior segment or panuveitis (factors that are currently not well known). Uveitis patients: * Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; * Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; * Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); * Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7. Control patients: * Blood sample (20ml): Additional 20 ml blood sample during the inclusion visit at the time of the surgical scheduled procedure for the needs of the biological collection; * Ocular sample (aqueous humor, vitreous): considered as surgical waste, the tissue residues will be collected during the scheduled surgical procedure for cataract or vitreoretinal surgery for the needs of the biological collection;
Interventions
DIAGNOSTIC_TESTcare strategy
Uveitis patients: * Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; * Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; * Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); * Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.
Sponsors
Groupe Hospitalier Pitie-Salpetriere
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
UVEITIS Patients: * Adult patients (≥ 18 years); * Non-infectious uveitis; * Intermediate, posterior or panuveitis; * Inflammatory activity requiring treatment with either one or more of the followings: * Systemic corticosteroids or periocular or intravitreal injections of corticosteroids; * Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.; * Biotherapy: infliximab, adalimumab, tocilizumab; * Patients with health insurance; * Written Informed consent obtained at enrolment in the study. Control patients: * Adult patients (≥ 18 years); * Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery; * Patients with health insurance; * Written Informed consent obtained at enrolment in the study.
Exclusion criteria
Uveitis Patients: * Isolated anterior uveitis ; * Inactive disease defined as: * Absence of inflammatory chorioretinal and/or inflammatory retinal vascular lesion; * Anterior chamber cell grade\< 0.5+; * Vitreous haze grade \<0.5+; * Pregnant or breastfeeding woman at the inclusion visit; * Patient under legal protection ( curatelle or tutelle ); * Patient denied freedom by a legal or administrative order. Control patients: * Pregnant or breastfeeding woman; * Unscheduled (urgent) cataract or vitreoretinal surgery; * Patient under legal protection ( curatelle or tutelle ); * Patient denied freedom by a legal or administrative order.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Imaging database development | 60 months | To develop an imaging database of Non-Infectious Uveitis of the posterior segment (NIUPS) using multimodal imaging |
| Biological constitution | 60 months | To Constitute a biological collection of ocular and blood samples of NIUPS patients and controls |
| medico economic costs estimation | 60 months | To estimate the current costs of treatment by ensuring linkage of cohort patients to the national claims database |
Outcome results
None listed